Cara Therapeutics reported $2.57M in Sales Revenues for its fiscal quarter ending in March of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Chugai Pharma JPY 404.7B 63.1B Sep/2026
Cipla INR 74.04B 2.85B Sep/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 2.6M 3.75M Jun/2026
CSL USD 8.33B 4.79B Dec/2025
Grifols EUR 2B 306.7M Mar/2026
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
J&J USD 25.4B 89M Sep/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Pacira USD 176.65M 15.75M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
RedHill Biopharma USD 1.29M 722K Jun/2024
Supernus Pharmaceuticals USD 226.8M 7.7M Sep/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024